BioSpace News Archive

United Health Products, Inc. announced that four surgeons who participated in the recently completed human clinical trial for HemoStyp are preparing and submitting a journal article entitled Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting for peer review.

Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th

REDWOOD CITY, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) has initiated the ECLIPSE trial, a 10,000-patient registrational study to evaluate the performance of its LUNAR-2 blood test to detect colorectal cancer (CRC) in average-risk adults. The test is intended to improve CRC screening rates by offering a simpler blood test that overcomes barriers associated with current testing methods. The U.S. Preventive Services Task Force recommends screening average-ris

Q3 revenues up 20.2% year-over-year to a record $607.3 million

Newly Formed Clinical-Stage Biotechnology Company to Develop Treatments for Rare Pediatric Neurodegenerative Diseases

NantHealth, Inc., a next-generation, evidence-based, personalized healthcare company, announced its new customer, Wexford Health Sources, Inc.

Viz.ai, the developer of the first synchronized healthcare software using artificial intelligence, announced a $50 million Series B funding.

United Therapeutics Corporation announced that it will report its third quarter 2019 financial results before the market opens on Wednesday, October 30, 2019.

Revenue in the third quarter of 2019 grew 3 percent, driven by 8 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, and Cyramza, contributed 12 percentage points of revenue growth and represented approximately 44 percent of total revenue.

Avivagen Inc. announces that it has received approval by the TSX Venture Exchange to extend the expiry date of certain of its outstanding warrants.